Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Risk of Incident Immune-mediated Inflammatory Diseases (IMID) in Patients Treated With Biologics and Immunosuppressive Drugs for a Single IMID

Next Previous
Trial Profile

Risk of Incident Immune-mediated Inflammatory Diseases (IMID) in Patients Treated With Biologics and Immunosuppressive Drugs for a Single IMID

Status: Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 26 Apr 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Adalimumab (Primary) ; Baricitinib (Primary) ; Brodalumab (Primary) ; Guselkumab (Primary) ; Ixekizumab (Primary) ; Risankizumab (Primary) ; Sarilumab (Primary) ; Secukinumab (Primary) ; Upadacitinib (Primary) ; Vedolizumab (Primary) ; Certolizumab pegol; Etanercept; Golimumab; Infliximab; Methotrexate; Tocilizumab; Tofacitinib; Ustekinumab
  • Indications Ankylosing spondylitis; Crohn's disease; Psoriasis; Psoriatic arthritis; Rheumatoid arthritis; Ulcerative colitis
  • Focus Therapeutic Use
  • Acronyms PROTECT-IMID

    • Most Recent Events

    • 21 Apr 2023 Status changed from not yet recruiting to active, no longer recruiting.
    • 31 Jan 2023 New trial record
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top